Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Beijing Wantai Biological Pharmacy Enterprise Co had a gross margin of 69.86% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Beijing Wantai Biological Pharmacy Enterprise Co Gross Margin % Related Terms
Beijing Wantai Biological Pharmacy Enterprise Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Wantai Biological Pharmacy Enterprise Co Gross Margin % Chart
Beijing Wantai Biological Pharmacy Enterprise Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Wantai Biological Pharmacy Enterprise Co Gross Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) has a Gross Margin % of 69.86% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. This is near median its historical median of 72.68. Over the past decade, Beijing Wantai Biological Pharmacy Enterprise Co's Gross Margin % has ranged from 49.32 to 89.54. According to the industry distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #433 out of 732 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Beijing Wantai Biological Pharmacy Enterprise Co's Gross Margin % too high?
Beijing Wantai Biological Pharmacy Enterprise Co's current Gross Margin % of 69.86% is near median its 10-year median of 72.68. Over the past 10 years, this metric has ranged from a low of 49.32 to a high of 89.54. The Biotechnology industry median Gross Margin % is 60.92. Beijing Wantai Biological Pharmacy Enterprise Co's value of 69.86% is 14.7% above this industry median. Based on the distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #433 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Beijing Wantai Biological Pharmacy Enterprise Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beijing Wantai Biological Pharmacy Enterprise Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #433 out of 732 companies for Gross Margin %. This places Beijing Wantai Biological Pharmacy Enterprise Co in the lower half of its industry. The industry median Gross Margin % is 60.92. Beijing Wantai Biological Pharmacy Enterprise Co's value of 69.86% is 14.7% above this benchmark. Historically, Beijing Wantai Biological Pharmacy Enterprise Co's own Gross Margin % has ranged from 49.32 to 89.54 over the past decade. While the company's 10-year median is 72.68 vs. the industry median of 60.92, Beijing Wantai Biological Pharmacy Enterprise Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Wantai Biological Pharmacy Enterprise Co's current Gross Margin % of 69.86% is 14.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Wantai Biological Pharmacy Enterprise Co's current Gross Margin % is 69.86%, which is near median its own 10-year median of 72.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Wantai Biological Pharmacy Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) is currently considered Possible Value Trap. The stock's GF Value™ is ¥42.09, compared to a current price of ¥29.20 — trading 30.6% below its estimated fair value. The current Gross Margin % is 69.86%, which is near median its 10-year median of 72.68 and 14.7% above the Biotechnology industry median of 60.92. Beijing Wantai Biological Pharmacy Enterprise Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392), the current Gross Margin % is 69.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued.
The current stock price of ¥29.20 is trading 30.6% below its estimated GF Value™ of ¥42.09.
GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.
Key valuation signals for SHSE:603392:
Gross Margin %: 69.86% (near median its 10-year median of 72.68)
GF Value™: ¥42.09 vs. price of ¥29.20 (30.6% below fair value)
Industry Position: 14.7% above the Biotechnology median (#433 of 732)
No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Wantai Biological Pharmacy Enterprise Co Business Description
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
53GF Score
Get the complete analysis for SHSE:603392
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603392 has been successfully added to your 
